Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 4, 2003, Pages 406-416

  Nyland, Susan B ^a,b   Cao, Chuanhai ^a   Bai, Yun ^a   Loughran, Thomas P ^b   Ugen, Kenneth E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Coinfection; HIV 1; HTLV I; IFN ; IL 2; In vitro; Morphine; RT activity

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; MORPHINE; NALOXONE; OPIATE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; SUPERINFECTION; VIRUS CULTURE; VIRUS INFECTION;

BASE SEQUENCE; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DNA PRIMERS; GENE EXPRESSION REGULATION; HIV INFECTIONS; HTLV-I INFECTIONS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; MORPHINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0037379471     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304010-00010     Document Type: Article

References (63)

1. CDC. Drug associated HIV transmission continues in the United States. 2000. Available at: http://www.cdc.gov/pubs/facts/idu.htm.
2. Pancake BA, Zucker-Franklin D, Marmor M, et al. Determination of the true prevalence of infection with the human T-cell lymphotropic viruses (HTLV-I/II) may require a combination of biomolecular and serological analyses. Proc Assoc Am Physicians 1996; 108:444-8.
3. Manns A, Hisada M, Genade LL. Human T-lymphotropic virus type I infection. Lancet 1999;353:1951-8.
4. Ognjan AF, Lewandowski CA, Belian BT, et al. The emerging role of HTLV-I/II and HIV-1 among intravenous drug users in Detroit. Henry Ford Hosp Med J 1992;40:131-5.
5. Visconti A, Visconti L, Bellocco R, et al. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6: 1228-37.
6. Page JB, Lai SH, Chitwood DD, et al. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet 1990;335:1439-41.
7. Freeman RC, Rodriguez GM, French JF. Seroprevalence and risk factors associated with HTLV-I/II infection in injection drug users in northern New Jersey. J Addict Dis 1995;14:51-66.
8. Telzak EE, Hershow R, Kalish LA, et al. Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19: 513-8.
9. Khabbaz RF, Douglas JM, Jr, Judson FN, et al. Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA. J Infect Dis 1990;162:241-4.
10. Lee HH, Weiss SH, Brown LS, et al. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle Atlantic and central regions of the USA. J Infect Dis 1990;162:347-52.
11. Jiang CL, Xu D, Lu CL, et al. Interleukin-2: structural and biologic relatedness to opioid peptides. Neuroimmunomodulation 2000;8: 20-4.
12. Scheel-Toellner D, Wang K, Henriquez N, et al. Cytokine-mediated inhibition of apoptosis in non-transformed T cells and neutrophils can be dissociated from protein kinase B activation. Eur J Immunol 2002;32:486-93.
13. Grimm MC, Ben-Baruch A, Taub DD, et al. Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J Exp Med 1998;188:317-25.
14. Madden JJ, Whaley WL Ketelsen D. Opiate binding sites in the cellular immune system: expression and regulation. J Neuroimmunol 1998;83:57-62.
15. Madden JJ, Whaley WL, Ketelsen D, et al. The morphine-binding site on human activated T-cells is not related to the mu opioid receptor. Drug Alcohol Depend 2001;62:131-9.
16. Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol 1998;83:63-9.
17. Roy S, Balasubramanian S, Sumandeep S, et al. Morphine directs T cells toward T(H2) differentiation. Surgery 2001;130:304-9.
18. Sacerdote P, Manfredi B, Mantegazza P, et al. Antinoceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997;121:834-40.
19. Nair MP, Schwartz SA, Polasani R, et al. Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 1997;4:127-32.
20. Singhal PC, Kapasi AA, Reddy K, et al. Morphine promotes apoptosis in Jurkat cells. J Leukoc Biol 1999;66:650-8.
21. Sueoka E, Sueoka N, Kai Y, et al. Anticancer activity of morphine and its synthetic derivative, KT-90, mediated through apoptosis and inhibition of NF-kappaB activation. Biochem Biophys Res Commun 1998;252:566-70.
22. Peterson PK, Sharp B, Gekker G, et al. Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest 1987;80:824-31.
23. McCarthy L, Wetzel M, Sliker JK, et al. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001;62:111-23.
24. Peterson PK, Sharp BM, Gekker G, et al. Opiates, human peripheral blood mononuclear cells, and HIV. Adv Exp Med Biol 1991; 288:171-8.
25. Peterson PK, Gekker G, Schut R, et al. Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection. Adv Exp Med Biol 1993;335:181-8.
26. Rouveix B. Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. Therapie 1992; 47:503-12.
27. Roy S, Cain KJ, Chapin RB, et al. Morphine modulates NF kappa B activation in macrophages. Biochem Biophys Res Commun 1998; 245:392-6.
28. Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995;83:500-8.
29. Hanon E, Goon P, Taylor GP, et al. High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. Blood 2001;98: 721-6.
30. Kubota R, Kawanishi T, Matsubara H, et al. HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J Neuroimmunol 2000; 102:208-15.
31. Zhang Q, Lee B, Korecka M, et al. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia. Leuk Res 1999;23:373-84.
32. Tomita N, Miyahara M, Satoh H, et al. Detection of reverse transcriptase activity by enzyme-linked immunosorbent assay in human immunodeficiency virus type 1. Acta Med Okayama 1995;49: 69-73.
33. Odawara F, Abe H, Kohno T, et al. A highly sensitive chemiluminescent reverse transcriptase assay for human immunodeficiency virus. J Virol Methods 2002;106:115.
34. Ekstrand DH, Awad RJ, Kallander CF, et al. A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation. Biotechnol Appl Biochem 1996;23:95-105.
35. Bernabei P, Coccia EM, Rigamonti L, et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 2001;70:950-60.
36. Zarozinski CC, McNally JM, Lohman BL, et al. Bystander sensitization to activation-induced cell death as a mechanism of virus-induced immune suppression. J Virol 2000;74:3650-8.
37. Beilke MA, Greenspan DL, Impey A, et al. Laboratory study of HIV-1 and HTLV-I/II coinfection. J Med Virol 1994;44:132-43.
38. Bessinger R, Beilke M, Kissinger P, et al. Retroviral coinfections at a New Orleans HIV outpatient clinic. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:67-71.
39. Casseb J, Caterino-de-Araujo A, Hong MA, et al. Prevalence of HTLV-I and HTLV-II infections among HIV-1-infected asymptomatic individuals in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo 1997;39:213-5.
40. Chavance M, Neisson-Vernant C, Quist D, et al. HIV/HTLV-I coinfection and clinical grade at diagnosis. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:91-5.
41. Giacomo M, Franco EG, Claudio C, et al. Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression. Eur J Epidemiol 1995;11:527-33.
42. McArthur JC, Griffin JW, Cornblath DR, et al. Steroid-responsive myeloneuropathy in a man dually infected with HIV-1 and HTLV-I. Neurology 1990;40:938-44.
43. Nadler JP, Bach MC, Godofsky E. Management of coinfection with human immunodeficiency virus and human T-cell lymphotropic virus type I [letter]. Clin Infect Dis 1996;23:415.
44. Pierik LT, Murphy EL. The clinical significance of HTLV-I and HTLV-II infection in the AIDS epidemic. AIDS Clin Rev 1991;39-57.
45. + lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:308-11.
46. Pacifici R, di Carlo S, Bacosi A, et al. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int J Immunopharmacol 2000;22:603-14.
47. Polakiewicz RD, Schieferl SM, Gingras AC, et al. mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J Biol Chem 1998;273:23534-41.
48. Mulloy JC, Kislyakova T, Cereseto A, et al. Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J Virol 1998;72:8852-60.
49. Tsukahara T, Kannagi M, Ohashi T, et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol 1999;73:7981-7.
50. Hollsberg P. Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Microbiol Mol Biol Rev 1999;63: 308-33.
51. Kalinkovich A, Weisman Z, Bentwich Z. Chemokines and chemokine receptors: role in HIV infection. Immunol Lett 1999;68:281-7.
52. Arima N, Tei C. HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia. Leuk Lymphoma 2001;40:267-78.
53. Yoshida M. Molecular biology of HTLV-I: recent progress. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl):S63-8.
54. Sharp BM, Roy S, Bidlack JM. Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuro-immunol 1998;83:45-56.
55. Buggage RR, Levy-Clarke GA, Smith JA. New corneal findings in human T-cell lymphotrophic virus type 1 infection. Am J Ophthalmol 2001;131:309-13.
56. Franchini G, Ambinder RF, Barry M. Viral disease in hematology. Hematology (Am Soc Hematol Educ Program) 2000;409-23.
57. Merle H, Cabre P, Merle S, et al. A description of human T-lymphotropic virus type I-related chronic interstitial keralitis in 20 patients. Am J Ophthalmol 2001;131:305-8.
58. Murphy EL, Glynn SA, Fridey J, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis 1997;176:1468-75.
59. Murphy EL, Glynn SA, Fridey J, et al. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med 1999;159:1485-91.
60. Taylor GP, Tosswill JH, Matutes E, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 1999;22:92-100.
61. Casseb J, Souza T, Pierre-Lima MT, et al. Testing problems in diagnosing HTLV infection among intravenous drug users with AIDS in Sao Paulo City, Brazil. AIDS Res Hum Retroviruses 1997; 13:1639-41.
62. Pancake BA, Zucker-Franklin D. The difficulty of detecting HTLV-I proviral sequences in patients with mycosis fungoides. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:314-9.
63. Zehender G, De Maddalena C, Gianotto M, et al. High prevalence of false-negative anti-HTLV type I/II enzyme-linked immunosorbent assay results in HIV type I-positive patients. AIDS Res Hum Retroviruses 1997;13:1141-6.